Myelo Therapeutics Gmbh
CAGE Code: DP990
NCAGE Code: DP990
Status: Active
Type: Commercial Supplier
Summary
Myelo Therapeutics Gmbh is an Active Commercial Supplier with the Cage Code DP990.
Address
Robert-Rossle Str. 10
Berlin
13125
Germany
Points of Contact
No Points of Contact...
Related Information
No Related Information...
Frequently Asked Questions (FAQ) for CAGE DP990
- What is CAGE Code DP990?
- DP990 is the unique identifier used by NATO Organizations to reference the physical entity known as Myelo Therapeutics Gmbh located at Robert-Rossle Str. 10, Berlin, 13125, Germany.
- Who is CAGE Code DP990?
- DP990 refers to Myelo Therapeutics Gmbh located at Robert-Rossle Str. 10, Berlin, 13125, Germany.
- Where is CAGE Code DP990 Located?
- CAGE Code DP990 is located in Berlin, Germany.
Contracting History for CAGE DP990 Most Recent 25 Records
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 9 Sep 2022
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 11 May 2023
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 14 Sep 2021
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 31 Mar 2022
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 14 Aug 2020
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 10 Jul 2023
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 27 Jan 2023
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 17 Nov 2020
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 30 Apr 2020
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 5 Jan 2022
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 13 Apr 2023
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 15 Sep 2023
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,728,096.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 29 Oct 2021
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 28 Apr 2021
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Ipp: Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 16 Nov 2022
- Ipp: Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 2 Mar 2021
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 8 Jun 2021
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00005
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- 28 Apr 2022
- Development Of Myelo001 As An Orally Applied Medical Countermeasure For The Treatment Of Hematopoietic Acute Radiation Syndrome
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,508,796.00
- Department Of Health And Human Services (Hhs)